Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for its animal health business Merial – the latest in a trend for multi-billion swaps in big pharma. The deal ...

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US.

Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, ...

NORTHAMPTON, MA / ACCESS Newswire / June 16, 2025 / In remote communities in Argentina, access to quality healthcare is a challenge for many different reasons, including a strong reliance on paper ...

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat generalised pustular psoriasis (GPP) flares.

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.